AA
RANI icon

ACT Advisors’s Rani Therapeutics RANI Stock Holding History

ACT Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3K Hold
14,806
– – ﹤0.01% 80
2026
Q1 		$10.9K Sell
14,806
-1,256
-8% -$1.6K ﹤0.01% 75
2025
Q4 		$21.7K Buy
16,062
+1,256
+8% +$1.9K 0.01% 62
2025
Q3 		$7.4K Buy
+14,806
New +$7.72K ﹤0.01% 72

Other funds holding RANI

KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
WDL
Well Done LLC Holland, Michigan $743M AUM 22.58% 1-Year Est. Return
M
MOTCO San Antonio, Texas $1.17B AUM 23.84% 1-Year Est. Return
TIA
Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

ACT Advisors's RANI Position: Q2 2026 in Review

ACT Advisors held its Rani Therapeutics (RANI) position steady in Q2 2026 at 14,806 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #80.

ACT Advisors first reported a position in RANI in Q3 2025 and has held it in 4 quarters since. The position peaked at $21.7K in Q4 2025. 13 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • ACT Advisors held 14,806 shares of Rani Therapeutics worth $11.3K as of Q2 2026.
  • ACT Advisors left its Rani Therapeutics share count unchanged in Q2 2026.
  • Rani Therapeutics made up ﹤0.01% of ACT Advisors's portfolio in Q2 2026, its #80 holding.
  • ACT Advisors first reported a position in Rani Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • ACT Advisors's Rani Therapeutics position peaked at $21.7K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on ACT Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.